<
https://www.theguardian.com/society/article/2024/jun/03/extremely-impressive-melanoma-jab-trial-results-excite-doctors>
"The world’s first personalised mRNA cancer vaccine for melanoma halves the
risk of patients dying or the disease returning, according to trial results
that doctors described as “extremely impressive”.
Melanoma affects more than 150,000 people a year globally, according to 2020
figures from World Cancer Research Fund International.
Patients who received the vaccine after having a stage 3 or 4 melanoma removed
had a 49% lower risk of dying or the disease recurring after three years, data
presented at the world’s largest cancer conference showed. The NHS in the UK is
among the organisations testing the jab.
A primary investigator on the study, oncologist Prof Georgina Long, said the
average risk of recurrence after surgery for the cohort of advanced cancer
patients was 50%.
“Although we do need to look at the five and 10-year numbers, most of the risk
of recurrence in this group occurs in that first two years,” the 2024
Australian of the Year said.
The 157 patients in the phase 2b trial had high-risk melanomas and either had
the jab, developed by Moderna and Merck, alongside the immunotherapy Keytruda
or were given only Keytruda.
The vaccine and the Keytruda brought the risk of recurrence down to 25%, Long
said. However, she cautioned the results were a “signal” with a larger trial
needed to evaluate the true impact better.
The 2.5-year recurrence-free survival rate for the jab in combination with
Keytruda was 74.8%, compared with 55.6% for Keytruda alone, delegates at the
American Society of Clinical Oncology (ASCO) annual meeting in Chicago heard.
“We are encouraged by the latest results,” said Kyle Holen, Moderna’s head of
development, therapeutics and oncology. “These findings reinforce our
commitment to advancing this innovative treatment.”"
Via
Fix the News:
<
https://fixthenews.com/good-news-water-sanitation-hygiene-poverty-cambodia-barn-owls-uk/>
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
